Ross River Virus

Ross River virus disease is a mosquito borne infectious disease caused by Ross River virus (RRV), belonging to the Alphavirus virus genus, mainly prevalent in South Pacific regions such as Australia and Papua New Guinea. The virus is transmitted through mosquito bites, and typical symptoms include joint pain, rash, fever, and fatigue. Although not fatal, it can cause weakness in patients for several months. The natural hosts are mainly marsupials. In 2017, the most serious outbreak in nearly 10 years occurred in Victoria, Australia, with over 1000 infected people. The virus was first isolated from mosquitoes near the Ross River in Queensland, Australia. The spread of viruses is related to humid climates, and heavy rainfall in spring can cause a significant increase in mosquito density.

Figure 1. Molecular and cellular aspects of disease pathogenesis of Ross River virus.( Rulli, Nestor E., et al.2005)

Historical Background

In the early 20th century, during the outbreak of "epidemic polyarthritis" in the South Pacific and Oceania, alphavirus was the top suspect. Compared to the profound viral polyarthritis caused by the Chikungunya virus, the disease in Australia appears to be milder. Serological testing suggests that an unknown new species of alphavirus may be a potential culprit. In 1959, a new alphavirus was identified on mosquitoes captured near the Ross River in Townsville, Queensland, Australia. Further serological tests have shown that patients suffering from "epidemic polyarthritis" in Queensland have antibodies to the virus. So the new virus was named "Ross River virus", and the disease was called "Ross River fever". In 1972, it was determined that RRV extracted from human serum could potentially kill mice. However, the serum containing the virus used came from a healthy child with a history of illness. This evidence confirms the established link between RRV and Ross River fever. Later, RRV caused a series of outbreaks of polyarthritis in Fiji, Samoa, and the Cook Islands, and patients were isolated during 1979. In 1985, RRV caused Ross River fever in Australia and the patient was isolated.

Laboratory Research

The study of RRV was recently facilitated by a mouse model. Mice are naturally infected with RRV, leading to diseases similar to humans, such as limb arthritis or joint pain. The disease of mice is similar to that of humans, showing a large infiltration of macrophages including immunogathogenic cells and exacerbating the disease. In addition, recent data suggests that serum component C3 directly causes disease, as mice lack C3 protein and therefore do not transmit this severe disease. This immune-mediated pathology is closely linked to the recognition of RRV-specific antigens by the mouse immune system, with RRV Envelope Antigen (comprising E1/E2 glycoproteins) acting as a major immunogen to trigger immune activation, while RRV Nonstructural 2 Antigen supports viral replication and modulates host immunity—both subtly shaping disease progression in mice. Beyond structural antigens, viral nonstructural proteins also contribute to RRV pathogenesis in mice: RRV Nonstructural 2 (nsP2), a multifunctional protein critical for RRV genome replication and viral RNA processing, has been implicated in modulating host immune responses and enhancing viral fitness. Studies in the mouse model suggest that nsP2 may interfere with host antiviral signaling pathways (e.g., interferon responses) or regulate the expression of pro-inflammatory cytokines, indirectly promoting the immunopathogenic macrophage infiltration and tissue damage observed in arthritic joints.

Treatment Options

There is no specific antiviral therapy for RRV. Management focuses on symptomatic relief:

• Non-steroidal anti-inflammatory drugs (NSAIDs) to alleviate pain and inflammation.
• Physical therapy and gentle exercise to improve joint mobility in chronic cases.
• Rest and hydration during the acute phase to support recovery.

Anti-RRV Antibodies

Ross River Virus Antigens